Ligand seeks to outlicense Glycomed's Galardin for corneal ulcers, keeps cell adhesion molecule program.
Executive Summary
LIGAND SEEKS GALARDIN TOPICAL OUTLICENSE; KEEPS CELL ADHESION MODULATORS program for inflammation, as well as a "tightly focused" matrix metalloproteinase inhibitor program in cancer, Ligand Pharmaceuticals announced Aug. 10. The company obtained the programs through its May 18 acquisition of Glycomed ("The Pink Sheet" Feb. 13, T&G-3). Ligand said these two programs, the former in collaboration with the Japanese firm Sankyo, "represent the value enhancement we are looking for."